(Q34734521)

4 August 2017

1 reference

title

Aromatase inhibitors in breast cancer therapy. (English)

1 reference

4 August 2017

author name string

Robert W Brueggemeier

series ordinal

1

1 reference

4 August 2017

publication date

1 April 2002

1 reference

Expert Review of Anticancer Therapy

4 August 2017

published in

1 reference

4 August 2017

volume

2

1 reference

4 August 2017

issue

2

1 reference

4 August 2017

page(s)

181-191

1 reference

Human aromatase in high yield and purity by perfusion chromatography and its characterization by difference spectroscopy and mass spectrometry

4 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2.2.181

Tamoxifen: toxicities and drug resistance during the treatment and prevention of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2.2.181

Binding characteristics of aromatase inhibitors and phytoestrogens to human aromatase

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2.2.181

Biochemical and molecular aspects of aromatase

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2.2.181

Aromatase and its inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2.2.181

Use of aromatase inhibitors in breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2.2.181

Inactivation of aromatase in vitro by 4-hydroxy-4-androstene-3,17-dione and 4-acetoxy-4-androstene-3,17-dione and sustained effects in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2.2.181

The Effect of an Aromatase Inhibitor, 4-Hydroxy-4-Androstene- 3,17-Dione, On Estrogen-Dependent Processes in Reproduction and Breast Cancer11

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2.2.181

4-Hydroxyandrostenedione in treatment of postmenopausal patients with advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2.2.181

Formestane. A review of its pharmacological properties and clinical efficacy in the treatment of postmenopausal breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2.2.181

Enzyme-generated intermediates derived from 4-androstene-3,6,17-trione and 1,4,6-androstatriene-3,17-dione cause a time-dependent decrease in human placental aromatase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2.2.181

Novel aromatase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2.2.181

Vorozole, a specific non-steroidal aromatase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2.2.181

Proceedings: Medical adrenalectomy using aminoglutethimide and dexamethasone in advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2.2.181

Endocrine therapy in the treatment of metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2.2.181

A randomised trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2.2.181

The minimal effective exemestane dose for endocrine activity in advanced breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2.2.181

Pharmacology and clinical experience with exemestane

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2.2.181

21 January 2018

Identifiers

DOI

10.1586/14737140.2.2.181

1 reference

4 August 2017

1 reference